Manager TitleAgeSince
Chief Executive Officer 53 30/08/2022
Director of Finance/CFO 55 02/05/2023
Chief Tech/Sci/R&D Officer 51 -
Director TitleAgeSince
Director/Board Member 53 01/09/2015
Chairman 71 15/04/2021
Director/Board Member 59 15/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.51M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.24%-1.34%+3.41%+34.31% 48.3B
-4.00%-2.43%+328.34%+696.81% 44.51B
-1.02%-2.08%+28.47%+32.60% 43.8B
+1.12%+0.01%+6.03%+110.10% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.44%-2.39%-8.51%-13.49% 24.53B
Average +0.63%-0.20%+52.93%+125.19% 43.73B
Weighted average by Cap. +1.01%-0.50%+56.91%+133.66%
Logo Amniotics AB
Amniotics AB (publ) is a Sweden-based biotech company that develops cell therapy drugs based on mesenchymal stem cells from amniotic fluid in its in-house GMP licensed facility. Amniotics' own marker technology is used to identify and select stem cells for different tissue types; Lung (PulmoStem), Brain (CogniStem), Kidney (NephroStem), Skin (CutiStem). It allows for selecting the type of cell to be used for specific tissue. The company has developed a process - patented in all steps - which includes collection of amniotic fluid, with a medical device developed by Amniotics, followed by sorting and propagation of stem cells and packaging of product in ampoules in its own GMP facility. Amniotics is a technology and service provider to Universities, Hospitals, and the Biopharmaceutical industry.
Employees
4